Literature DB >> 8284043

CGS-19755 is neuroprotective during repetitive ischemia: this effect is significantly enhanced when combined with hypothermia.

A Shuaib1, S Ijaz, R Mazagri, A Senthilsevlvan.   

Abstract

In small animals the damaging effects of repetitive ischemia are more severe than a single insult of similar duration. Prolonged release of glutamate may correlate with the degree of damage. We report the protective effects of CGS-19755 (an N-methyl-D-aspartate receptor blocker), hypothermia or CGS-19755 in combination with mild hypothermia, in a gerbil model of repetitive ischemia. We used 3 min of forebrain ischemia and repeated it for a total of three times as 1-h intervals. Damage was assessed seven days after the insult. In the group where only CGS-19755 was used, significant neuronal protection was evident in the hippocampus (CA1 and CA3), striatum, and medial geniculate nucleus. With hypothermia significantly less damage was seen in the cerebral cortex, hippocampus (CA1 and CA4), and substantia nigra reticulata. When CGS-19755 was combined with mild hypothermia the effects of repetitive ischemia were completely abolished in all but one gerbil. Compared to hypothermia alone, significant protection was seen in the cerebral cortex, hippocampus (sibiculum, CA1 and CA4), striatum, medial geniculate nucleus, thalamus, and substantia nigra reticulata. The use of N-methyl-D-aspartate receptor blockers may protect the brain in repetitive ischemia. Combination with hypothermia may further enhance this protection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8284043     DOI: 10.1016/0306-4522(93)90137-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

1.  The role of taurine in neuronal protection following transient global forebrain ischemia.

Authors:  S H Khan; A Banigesh; A Baziani; K G Todd; H Miyashita; M Eweida; A Shuaib
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

2.  Therapeutic applications of hypothermia in cerebral ischaemia.

Authors:  Bruno P Meloni; Frank L Mastaglia; Neville W Knuckey
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 3.  Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease.

Authors:  Kota Kurisu; Jong Youl Kim; Jesung You; Midori A Yenari
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

4.  Antiischemic effects of topiramate in a transient global forebrain ischemia model: a neurochemical, histological, and behavioral evaluation.

Authors:  S H Khan; Sandra Lea Wright; Ali Banigesh; Hiro Miyashita; Kathryn Todd; Susan Jean Hemmings; Tom Wishart; Ashfaq Shuaib
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

5.  Superoxide dismutase, catalase, and U78517F attenuate neuronal damage in gerbils with repeated brief ischemic insults.

Authors:  D Truelove; A Shuaib; S Ijaz; S Richardson; J Kalra
Journal:  Neurochem Res       Date:  1994-06       Impact factor: 3.996

6.  Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion.

Authors:  Zhenjun Tan; Xinlan Li; Kimberly A Kelly; Charles L Rosen; Jason D Huber
Journal:  Brain Res       Date:  2009-05-22       Impact factor: 3.252

7.  Delayed minocycline but not delayed mild hypothermia protects against embolic stroke.

Authors:  Chen Xu Wang; Tao Yang; Raza Noor; Ashfaq Shuaib
Journal:  BMC Neurol       Date:  2002-04-18       Impact factor: 2.474

Review 8.  Oxygen or cooling, to make a decision after acute ischemia stroke.

Authors:  Wen-Cao Liu; Xin-Chun Jin
Journal:  Med Gas Res       Date:  2016-12-30

Review 9.  Effects of Therapeutic Hypothermia Combined with Other Neuroprotective Strategies on Ischemic Stroke: Review of Evidence.

Authors:  Zheng Zhang; Linlei Zhang; Yuchuan Ding; Zhao Han; Xunming Ji
Journal:  Aging Dis       Date:  2018-06-01       Impact factor: 6.745

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.